NIH-Developed Candidate Dengue Vaccine Shows Promise in Early-Stage Trial
Monday, April 29, 2013
The trial results appeared in the April 1 issue of the Journal of Infectious Diseases.
Acumen Pharmaceuticals Announces First Close of Series A Financing
Monday, April 29, 2013
Proceeds will fund lead-drug candidate ACU-193 to proof of concept in Alzheimer’s disease.
Genticel Secures EUR 18.2 Million (USD 23.7 million) in Capital Funding
Friday, April 26, 2013
Dr. Rainer Strohmenger joins the supervisory board of Genticel.
AMRI and Ono Broaden SMARTSOURCING™ Collaboration
Friday, April 26, 2013
New agreement extends drug discovery and development collaboration between the companies.
SCM to Support BTG NDA
Friday, April 26, 2013
Will provide scale up for Varisolve launch.
Investigator Sponsored Phase I/II study of AXL1717 in Patients with Brain Tumors
Thursday, April 25, 2013
Phase I/II study with AXL1717 started in the United States.
Dezima In-Licenses CETP Inhibitor Program from MTPC
Thursday, April 25, 2013
World-renowned dyslipidemia experts join Dezima’s Scientific Advisory Board.
ThromboGenics Receives Positive CHMP Opinion for JETREA®
Wednesday, April 24, 2013
Positive opinion clears the way for the potential EMA approval of JETREA® as the first pharmacological option for the treatment of VMT, including when associated with macular hole of diameter less than or equal to 400 microns.
Galapagos Starts Phase 2A Study with GLPG0974 in Ulcerative Colitis
Tuesday, April 23, 2013
Study will deliver topline results early 2014.
|
|
|
|
|
|
